Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Fuxing Xiong"'
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 25, Iss 5, Pp 948-960 (2020)
Long noncoding RNA prostate cancer-associated transcript 1 (PCAT1) is oncogenic and causes progression of non-small cell lung cancer (NSCLC). We hypothesized that PCAT1 might be involved in the acquisition of chemoresistance of NSCLC cells to treatme
Externí odkaz:
https://doaj.org/article/d2a73ee819c54dd2985d9322a8386420
Autor:
Nana Huang, Chenchen Zhao, Xueyang Hu, Congjun Zhang, Fuxing Xiong, Wei Huang, Liangshan Da, Yuanyuan Shen, Hongyang Wu
Publikováno v:
Translational cancer research. 11(1)
Sintilimab is a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. We evaluated the safety and efficacy of sintilimab combined with chemotherapy and targeted therapy in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f60f40bd5a8b4691439ca587e90833
https://pubmed.ncbi.nlm.nih.gov/35261901
https://pubmed.ncbi.nlm.nih.gov/35261901
Publikováno v:
Annals of Palliative Medicine. 8:525-531
Background: To find the method of therapy of leptomeningeal metastasis (LM) to non-small cell lung cancer (NSCLC) patient with EGFR mutation ( EGFR +) but without T790M mutation. Methods: A retrospective analysis was reviewed for 5 NSCLC patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8194cb48b9ebea6faaf2b0a2c8b47982
https://doi.org/10.21037/apm.2019.10.13
https://doi.org/10.21037/apm.2019.10.13
Autor:
Hongyang, Wu, Nana, Huang, Chenchen, Zhao, Xueyang, Hu, Liangshan, Da, Wei, Huang, Yuanyuan, Shen, Fuxing, Xiong, Congjun, Zhang
Publikováno v:
Ann Transl Med
BACKGROUND: The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has not yet been reported. Therefore, we aimed to compare the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bfe954f43f5550624d84ce26fccce59
https://doi.org/10.21037/atm-22-544
https://doi.org/10.21037/atm-22-544
Publikováno v:
Journal of Cancer Research and Therapeutics. 18:576
The role of camrelizumab combined with chemotherapy as the second-line therapy in nonsquamous nonsmall cell lung cancer (NSCLC) remains unverified. The retrospective study investigated efficacy and safety of camrelizumab combined with chemotherapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d594cb66ea7449a26c79d96692fd26
https://doi.org/10.4103/jcrt.jcrt_855_21
https://doi.org/10.4103/jcrt.jcrt_855_21
Publikováno v:
Annals of palliative medicine. 9(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b77c444347275e8aa54cff2b13ea541
https://pubmed.ncbi.nlm.nih.gov/31865717
https://pubmed.ncbi.nlm.nih.gov/31865717